Kontigo Care: Gentle start to 2023 - Redeye

Redeye provides an update on Kontigo Care following its Q1 2023 report. The report indicates a slightly weaker performance than anticipated. Still, we are optimistic about the impact of price increases, robust business activity, and the ongoing studies associated with the Previct Drug product. We revise our near-term projections in light of a weaker-than-expected license increase in Q1’23 and adjust our Base case to SEK10.5 per share (SEK11).

Länk till analysen i sin helhet: https://www.redeye.se/research/908837/kontigo-care-gentle-start-to-2023?utm_source=finwire&utm_medium=RSS